<
Conference agenda
Welcome and introductions Existing drugs and therapiesMedical need Examining the Resistance Problems Resistance epidemiologyDevelopment and emerging of resistanceResistance problems in 10 years from now What’s out there – Research and Development Global R&D activities – overview on pipelinesGap between R&D activities and medical needPartnering activities An Examination of the Market 10yrs from now The market in 10 yearsOpportunity assessment Discussion and questions – review of the session Close of Executive Briefing Chairman's Opening Remarks Professor Ian Chopra, Professor of Microbiology, Institute of Molecular & Cellular Biology, University of Leeds Dr Kenneth Tack, Executive Director, Pfizer The shape of current and future markets Current position The need for new antibiotics Antibiotic research Developments in antimicrobial agents Problems and solutions Where next?John Powers, MD, National Institute of Health Points to rememberIncreasing the efficiency in clinical trialsAntibiotic resistance and incentives for development THE REGULATORY ENVIRONMENT Dr Mair Powell, Medical Assessor, Licensing Division, , MHRA Requirements and expectationsProcesses that might facilitate drug developmentExamining the regulations MULTI-DRUG RESISTANCE IN KLEBSIELLA PNEUMONIAE Thomas Gootz, Senior Research Fellow, Pfizer Carbapenem-resistant K. pneumoniae encoding KPC-2 or KPC-3 enzymes are endemic in some hospitals in NYCDown-regulation of the phosphate porin PhoE in K. pneumoniae leading to carbapenem resistance has only recently been describedVery few alternative antibiotics with activity against such multi-resistant Klebsiella are availableKlebsiella is more commonly isolated in human infections than Pseudomonas aeruginosa or AcinetobacterMult-resistant Klebsiella may represent one of the biggest problems in nosocomial infections in the future NEW AND NOVEL ADVANCES IN DRUG DEVELOPMENT Dr Nachum Kaplan, Vice President, Microbiology, Affinium Pharmaceuticals New class of antibacterialsSpecific-spectrum agentHighly potent against all known MRSA phenotypesProven efficacious in animal modelsOrally bioavailable in humans (microdosing)In development as novel iv/oral MRSA agent ANTI-INFECTIVES IN THE DEVELOPMENT PIPELINE, PHASE 2 & PHASE 3 Dr PJ Turner, Associate Director, Infection Discovery, AstraZeneca R&D Anti-Gram-positive agents Anti-Gram-negatives Broad spectrum Anti-fungals Vaccines NOVEL APPROACH TO PRESERVING LONGEVITY OF NEW AND CURRENT BETA-LACTAM ANTIBIOTICS Dr Betsy Abraham-Van Parijs, Senior Director, Infectious Diseases Medicine Development Centre, GlaxoSmithKline Nora Kaarela, Chief Executive Officer, IPSAT Therapies NEW METHODS FOR NOVEL ANTIBIOTIC DISCOVERY Dr Jeff Hermes, Senior Director, Infectious Disease Research, Merck and Co Established antibiotics use limited number of mechanisms New structural classes addressing unexploited targets are urgently needed Novel screening approaches are keyDiscovery of platensimycin Future direction UPDATE GLYCYLCYCLINES - A NEW CLASS OF ANTIBIOTIC Dr E David G Macintosh, Medical Director Infectious Diseases, Wyeth Europa What progress has been madeLaunchIndustry advancementsTarget use and possible opportunities for disease/infection controlInsight into clinical trial results AR-709: A NOVEL ANTIBIOTIC DESIGNED TO OVERCOME RESISTANCE IN STREPTOCOCCI Dr Stephen Hawser, Director Microbiology, Arpida Rising drug resistance in streptococci and medical needs Developing new drugs for streptococcal targeted therapy DHFR, an under-exploited antibacterial target Discovery of novel anti-streptococcal diaminopyrimidines Clinical candidate AR-709 Chairman’s Closing Remarks and Close of Day One Chairman's Opening Remarks Professor Ian Chopra, Professor of Microbiology, Institute of Molecular & Cellular Biology, University of Leeds MRSA PREVALENCE AND TREATMENT Ron Van Amsterdam, Senior Clinical Research Manager, Astellas Pharma Europe Epidemiologic aspectsCurrent care and needsFuture therapeutic options DEVICE-RELATED INFECTIONS William Weiss, Director, Drug Evaluation, Cumbre Pharmaceuticals Scope of infected devicesProblems associated with treatmentIn vitro / In vivo models of device infectionsCurrent therapyNew and emerging agentsDr Nafsika Georgopapadakou, Vice President, Infectious Diseases, MethylGene CHEMICAL POST-EVOLUTION OF ANTIBACTERIAL NATURAL PRODUCTS Dr Dieter Haebich, Director, Medicinal Chemistry, Bayer Healthcare A G Examining lead structure variantsStructural and Physiochemical requirements for antibacterial activity ANTIBACTERIAL AND ANTIFUNGAL DRUG RESISTANCE Dr Neil S Ryder, Executive Director, Infectious Diseases, Novartis Basic mechanisms of resistance, common features and differences between bacteria and fungiImpact of resistance on selection of drug targets, with some recent examplesWhat can antifungal and antibacterial drug discovery learn from each other NOVEL ß-LACTAM ANTIBIOTICS AND INHIBITOR COMBINATIONS Professor Malcolm Page, Head, Biology, Basilea Pharmaceutica Rising drug-resistance in Gram-negative bacteria, especially Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter species ß-Lactam resistance in Gram-negative bacteria ß-Lactamase inhibitors ß-Lactams with enhanced stability towards ß-lactamases New ß-lactam combinations with activity against "pan-resistant" Gram-negative pathogens Lloyd Czaplewski, Director, Research, Prolysis New class of antibacterialPotent against MRSA & MRSE clinical isolatesEfficacious in animal models DISCOVERY OF NEW ANTIVIRULENCE DRUGS Alexis Denis, Vice President, Director, Medicinal Chemistry, Mutabilis New antibacterial paradigm THE USE OF MODIFIED ANTIMICROBIALS PEPTIDES AS ANTIBIOTICS Dr Søren Kjaerulff, Director, Antimicrobials Peptides, Molecular Biotechnology, R&D, Novozymes Update of Plectasin, a new antibiotic for treatment of resistant Gram positive bacterial infectionsPlectasin - the first Defensin from microorganismsNew class of antibacterialsPreclinical lead candidateGram positive activity incl. MRSA, VRSA & PRSPNew AMPs for Gram negative bacterial and fungal infections ANTIBIOTICS TARGETING THE RIBOZYME Dr Joyce Sutcliffe, Chief Research Scientist, Rib-X Pharmaceuticals The 50S ribosomal subunit provides multiple antibacterial target sites 3D knowledge provides insight for circumventing target-based resistance Use of proprietary gram-positive 50S structure yields important understanding for drug design SBDD enrichment for drug-like properties and good binding before compounds are synthesizedRib-X approach yields distinct antibiotic classes for different market segments Chairman’s Closing Remarks and Close of Day One
Workshops
Crowne Plaza Hotel - The City 25 April 2007 London, United Kingdom
copyright ©
2024
SAE Media Group
|